PILA PHARMA AB

PILA PHARMA AB (publ) is a Swedish biotech company focused on developing TRPV1 antagonists as novel treatments for type 2 diabetes, obesity, and other inflammatory diseases. The company recently shared recordings of presentations by CEO Gustav H. Gram, discussing their lead candidate, XEN-D0501, and its potential in treating obesity and diabetes. XEN-D0501 has shown promise in clinical trials, demonstrating good tolerability and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. The company is preparing for further trials to explore its maximal tolerable dose and efficacy in weight reduction. PILA PHARMA also explores the use of XEN-D0501 for erythromelalgia and abdominal aorta aneurysm, with ongoing research collaborations and plans for proof-of-concept studies. The company aims to address the growing global challenges of obesity and diabetes, which are linked to significant health risks and economic burdens.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs targeting the TRPV1 receptor for obesity and diabetes treatment. The company recently participated in an online investment presentation, discussing its approach and the industry's shift towards oral treatment solutions. PILA PHARMA's lead candidate, XEN-D0501, is a TRPV1 antagonist shown to be effective and well-tolerated in early clinical trials for obesity and type 2 diabetes. The company is preparing for further trials to assess the drug's safety and efficacy. Additionally, PILA PHARMA is exploring the use of XEN-D0501 for treating erythromelalgia and abdominal aorta aneurysm, with promising preclinical results. The company holds patents for TRPV1 antagonists and continues to advance its research and development efforts in these areas.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition for treating obesity and diabetes. CEO Gustav H. Gram discussed the company's goals and the broader market trends, including the 'Longevity' movement, on the 10X podcast. The podcast is available in English, with the PILA segment starting at 33:10. PILA PHARMA is focused on developing TRPV1 antagonists, specifically XEN-D0501, for treating type 2 diabetes and other inflammatory diseases. The company has completed successful phase 2a trials and is preparing for further clinical trials, aiming to identify the maximal tolerable dose and evaluate the safety of XEN-D0501 in people with obesity and type 2 diabetes. The company is also exploring treatments for erythromelalgia and abdominal aorta aneurysm, with promising preclinical results for XEN-D0501 in reducing aneurysm growth in mice. PILA PHARMA's projects are available for out-licensing, and the company continues to advance its research and development efforts.

PILA PHARMA AB, a Swedish biotech company focused on developing novel oral drugs for obesity and diabetes using TRPV1 inhibition, is hosting an after-work event on June 11 in Stockholm. The event will feature updates from CEO Gustav H. Gram and Founder Dorte X. Gram on the company's progress and plans, as well as a Q&A session. PILA PHARMA is advancing its development candidate XEN-D0501, a TRPV1 antagonist, which has shown promise in clinical trials for obesity and type 2 diabetes. The company is also exploring its potential for treating erythromelalgia and abdominal aorta aneurysm. PILA PHARMA's shares are traded on Nasdaq First North Growth Market.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition for treating obesity and diabetes. The company invites investors to several upcoming events where CEO Gustav H. Gram will discuss the company's innovative treatments and market outlook. PILA PHARMA focuses on developing TRPV1 antagonists like XEN-D0501, which have shown potential in treating metabolic disorders. The company has completed two phase 2a trials demonstrating XEN-D0501's safety and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. PILA PHARMA is preparing for a new clinical trial to assess the maximal tolerable dose of XEN-D0501 for obesity and type 2 diabetes. The company also explores treatments for erythromelalgia and abdominal aorta aneurysm, with promising preclinical results for the latter. PILA PHARMA's shares are traded on Nasdaq First North Growth Market, Sweden.

PILA PHARMA AB, a Swedish biotech company, announced a recent interview with Helge Larsen from ProInvestor, Denmark's largest online forum for investors in biotechnology and pharmaceutical stocks. The interview, conducted in Danish, featured founder and CSO Dorte X. Gram discussing the company's development of a novel oral treatment for obesity and diabetes using a TRPV1 antagonist. The recording is available online, with an English subtitled version forthcoming. PILA PHARMA is listed on Nasdaq First North Growth Market, Sweden, and focuses on developing treatments for obesity, type 2 diabetes, erythromelalgia, and abdominal aorta aneurysm. Their lead candidate, XEN-D0501, has shown promise in clinical trials for improving insulin response and reducing cardiovascular biomarkers. The company is preparing for further clinical trials to assess safety and efficacy. PILA PHARMA also collaborates with Uppsala University on research for abdominal aorta aneurysms, where XEN-D0501 has shown potential in preclinical studies.

PILA PHARMA AB will participate in a 1-on-1 interview with Helge Larsen from ProInvestor on June 5, 2025. The interview will feature Founder and CSO Dorte X. Gram discussing the company's development of a novel oral treatment for obesity and diabetes using a TRPV1 antagonist. The discussion will cover topics such as the mode of action of TRPV1 antagonists, data supporting their use for metabolic diseases, and progress on their lead candidate, XEN-D0501. The interview will be conducted in Danish and transcribed to English, with the recording available on June 6, 2025. PILA PHARMA is a Swedish biotech company focused on developing TRPV1 antagonists for treating type 2 diabetes and other inflammatory diseases. Their lead candidate, XEN-D0501, has shown promising results in clinical trials for obesity and diabetes, and holds orphan drug designation for erythromelalgia. XEN-D0501 has demonstrated efficacy in reducing glucose intolerance and body weight gain in preclinical studies and has a good safety profile. The company is preparing for further clinical trials to assess the safety and efficacy of XEN-D0501. PILA PHARMA is also involved in research for treating erythromelalgia and abdominal aorta aneurysm, with ongoing studies and collaborations to explore the potential of XEN-D0501 in these areas. The company aims to address unmet needs in obesity and diabetes treatment, with a focus on developing accessible oral therapies.

PILA PHARMA AB held its annual general meeting on April 29, 2025, in Malmö, Sweden, where key decisions were made. The company's financial statements for 2024 were approved, and it was decided that no dividend would be distributed for that year. The board and CEO were granted discharge from liability for 2024. The meeting re-elected board members Dorte Xenia Gram, Richard Busellato, Lasse Richter Petersen, and Julie Waras Brogren, with Dorte Xenia Gram continuing as chair. Deloitte AB was re-elected as auditor, with Maria Ekelund as the lead auditor. The nomination committee will include Dorte Xenia Gram and Niels Raaschou. The board was authorized to issue new shares or financial instruments until the next annual meeting. PILA PHARMA is a Swedish biotech company focused on developing TRPV1 antagonists for treating type 2 diabetes and other inflammatory diseases. Its main asset is XEN-D0501, which has shown promise in clinical trials for obesity and type 2 diabetes. The company plans further trials to determine the maximum tolerable dose and assess safety and efficacy. PILA PHARMA also explores treatments for erythromelalgia and abdominal aorta aneurysm, with ongoing research collaborations and development plans.

PILA PHARMA AB, a Swedish biotech company, invites investors and interested parties to upcoming events where they will present their work on innovative treatments for obesity, diabetes, and other conditions. These events include a panel debate in Malmö on April 28, 2025, the Vator Life Science Summit in Stockholm on May 14, 2025, and the AktieInfo Investor Evening in Copenhagen on May 19, 2025. The company focuses on developing TRPV1 antagonists, specifically XEN-D0501, for treating type 2 diabetes, obesity, erythromelalgia, and abdominal aorta aneurysm. XEN-D0501 has shown promising results in clinical trials, demonstrating good tolerability and efficacy. PILA PHARMA continues to advance its research and development efforts, with plans for further clinical trials and ongoing collaborations. The company is publicly traded on Nasdaq First North Growth Market in Sweden.

PILA PHARMA AB (publ) reminds shareholders that April 23 is the last day to register for the Annual General Meeting on April 29, 2025, in Malmö, Sweden. Shareholders can attend in person or vote via proxy. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 antagonists for treating type 2 diabetes and other diseases. Their development candidate, XEN-D0501, has shown promise in clinical trials and has potential applications in obesity, diabetes, erythromelalgia, and abdominal aorta aneurysm. The company is preparing for further clinical trials to evaluate safety and efficacy. Obesity and diabetes are significant global health issues, and PILA PHARMA is working on potential treatments for these conditions. Erythromelalgia is a rare disease causing pain and redness, with no current treatments available. Abdominal aorta aneurysm affects many globally, and PILA PHARMA's research has shown potential in reducing its growth.